Cargando…

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023

The recommendations define the principles of diagnosis and treatment of hepatitis C virus (HCV) infection according to the latest knowledge. The main goal of the treatment of HCV infection is to eliminate the virus from the body, which in turn leads to stopping the progression or causes the regressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomasiewicz, Krzysztof, Flisiak, Robert, Jaroszewicz, Jerzy, Małkowski, Piotr, Pawłowska, Małgorzata, Piekarska, Anna, Simon, Krzysztof, Zarębska-Michaluk, Dorota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090994/ https://www.ncbi.nlm.nih.gov/pubmed/37064834 http://dx.doi.org/10.5114/ceh.2023.125957

Ejemplares similares

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020
por: Halota, Waldemar, et al.
Publicado: (2020)

Recommendations for treatment of hepatitis C. Polish Group of HCV Experts – 2015
por: Halota, Waldemar, et al.
Publicado: (2015)

Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016
por: Halota, Waldemar, et al.
Publicado: (2016)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Recommendations for the treatment of hepatitis B in 2017
por: Flisiak, Robert, et al.
Publicado: (2017)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Recommendations for the treatment of hepatitis C in 2017
por: Halota, Waldemar, et al.
Publicado: (2017)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
por: Flisiak, Robert, et al.
Publicado: (2021)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021)

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?
por: Tronina, Olga, et al.
Publicado: (2023)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Distribution of HBV genotypes in Poland
por: Świderska, Magdalena, et al.
Publicado: (2015)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
por: Pawłowska, Małgorzata, et al.
Publicado: (2019)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland
por: Grzeszczuk, Anna, et al.
Publicado: (2015)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
por: Dobrowolska, Krystyna, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
por: Domagalski, Krzysztof, et al.
Publicado: (2013)

Impact of Kidney Failure on the Severity of COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database
por: Flisiak, Robert, et al.
Publicado: (2023)

Distribution of HCV Genotypes in the Populations of Inmates in Polish Prison Potulice and Patients Hospitalised in Bydgoszcz
por: Tyczyno, Malgorzata, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rdn3u4291h064b0k776fkm7vvc